Aytu BioPharma Q2 revenue beats expectations

Reuters

02/04

<a href="https://laohu8.com/S/AYTUZ">Aytu BioPharma</a> <a href="https://laohu8.com/S/QTWO">Q2</a> revenue beats expectations

Overview

Pharmaceutical company's Q2 revenue beat analyst expectations
Adjusted EBITDA for Q2 beat analyst expectations

Outlook

Company did not provide specific financial guidance for future quarters or full year in press release

Result Drivers

SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA
INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$15.17 mln	$12.17 mln (3 Analysts)
Q2 Net Income		-$10.58 mln
Q2 Adjusted EBITDA	Beat	-$800,000	-$4.30 mln (3 Analysts)
Q2 Gross Profit		$9.62 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71

Press Release: ID:nACStMvP3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2608638826"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608638826\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608638826?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608638826","market":"nz","top_or_hot":-1,"title":"Aytu BioPharma Q2 revenue beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Pharmaceutical company's Q2 revenue beat analyst expectations</p></li><li><p>Adjusted EBITDA for Q2 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or full year in press release</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA</p></li><li><p>INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$15.17 mln</p></td><td><p>$12.17 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$10.58 mln</p></td><td></td></tr><tr><td><p>Q2 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$800,000</p></td><td><p>-$4.30 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$9.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71</p></li></ul><p>Press Release: <span>ID:nACStMvP3a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Q2 revenue beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Q2 revenue beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 05:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Pharmaceutical company's Q2 revenue beat analyst expectations</p></li><li><p>Adjusted EBITDA for Q2 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or full year in press release</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA</p></li><li><p>INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$15.17 mln</p></td><td><p>$12.17 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$10.58 mln</p></td><td></td></tr><tr><td><p>Q2 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$800,000</p></td><td><p>-$4.30 mln (3 Analysts)</p></td></tr><tr><td><p>Q2 Gross Profit</p></td><td></td><td><p>$9.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71</p></li></ul><p>Press Release: <span>ID:nACStMvP3a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL1N3YZ1BB:1","article_id":"2608638826","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608638826","pubTimestamp":1770153700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aytu BioPharma Q2 revenue beats expectationsOverviewPharmaceutical company's Q2 revenue beat analyst expectationsAdjusted EBITDA for Q2 beat analyst expectationsOutlookCompany did not provide specific","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AYTU":"Aytu BioScience, Inc."},"translate_title":"Aytu BioPharma第二季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"Aytu BioPharma Q2 revenue beats expectationsOverviewPharmaceutical company's Q2 revenue beat analyst expectationsAdjusted EBITDA for Q2 beat analyst expectationsOutlookCompany did not provide specific financial guidance for future quarters or full year in press releaseResult DriversSHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUAINVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectationsKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$15.17 mln$12.17 mln (3 Analysts)Q2 Net Income-$10.58 mlnQ2 Adjusted EBITDABeat-$800,000-$4.30 mln (3 Analysts)Q2 Gross Profit$9.62 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71Press Release: ID:nACStMvP3aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}